{"id":409960,"date":"2021-01-06T17:03:25","date_gmt":"2021-01-06T22:03:25","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=409960"},"modified":"2021-01-06T17:03:25","modified_gmt":"2021-01-06T22:03:25","slug":"iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/","title":{"rendered":"Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">DUBLIN, Ireland and CHICAGO, Jan.  06, 2021  (GLOBE NEWSWIRE) &#8212; Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that management will participate in the H.C. Wainwright BioConnect Conference\u00a0being held virtually from\u00a0January 11-14, 2021.\u00a0Corey Fishman, Chief Executive Officer, will provide a company overview and business update. The Company\u2019s presentation will be available on-demand through the H.C. Wainwright conference portal, beginning on\u00a0Monday, January 11th\u00a0at\u00a06:00 a.m. Eastern Time.<\/p>\n<p align=\"justify\">The presentation may also be accessed by visiting the \u201cInvestors\u201d section of the Company\u2019s website under the \u201cEvents and Presentations\u201d tab at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Rn1cvYZPZKnWkyYgAjKE2uC4pE_DuEU2z_Lj-F1UTDryK4tNrAm-5MKqanIx-j4UMKmz4pgJoYv4_UXr_U7-kg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.iterumtx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Iterum Therapeutics plc<\/strong>\n      <\/p>\n<p align=\"justify\">Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem. In some cases, forward-looking statements can be identified by words such as \u201cmay,\u201d \u201cbelieves,\u201d \u201cintends,\u201d \u201cseeks,\u201d \u201canticipates,\u201d \u201cplans,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cshould,\u201d \u201cassumes,\u201d \u201ccontinues,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cwill,\u201d \u201cfuture,\u201d \u201cpotential\u201d or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company\u2019s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside the Company\u2019s control, including the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, changes in regulatory requirements or decisions of regulatory authorities, the timing of approval of any submission, changes in public policy or legislation, commercialization plans and timelines, if oral sulopenem is approved, the actions of third-party clinical research organizations, suppliers and manufacturers, risks regarding intellectual property rights in product candidates and the ability to defend and enforce any such intellectual property rights, the accuracy of the Company\u2019s expectations regarding how far into the future the Company\u2019s cash on hand will fund the Company\u2019s ongoing operations, the sufficiency of the Company\u2019s cash resources and the Company\u2019s ability to continue as a going concern, the impact of COVID-19 and related responsive measures thereto, the Company\u2019s ability to maintain listing on the Nasdaq Capital Market, risks and uncertainties concerning the outcome, impact, effects and results of the Company\u2019s evaluation of corporate, organizational, strategic, financial and financing alternatives, including the terms, timing, structure, value, benefits and costs of any corporate, organizational, strategic, financial or financing alternative and the Company\u2019s ability to complete one at all, the price of the Company\u2019s securities and other factors discussed under the caption \u201cRisk Factors\u201d in its most recently filed Quarterly Report on Form 10-Q, and other documents filed with the SEC from time to time. Forward-looking statements represent the Company\u2019s beliefs and assumptions only as of the date of this press release. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Judy Matthews<br \/>Chief Financial Officer <br \/>312-778-6073<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6FxDgZUA0khdq-AF6JWxZz0A7isnOPDiT1p-h7l9OH9pi3AxV0l1RZCqnyBe_gb8TxF1IgkCNKtRmNf6ZigUsA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">IR@iterumtx.com<\/a><\/u><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTc3OCMzOTA3Nzk4IzIxMjA2NzM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/4551230b-f3d8-4c73-9239-69dbca197843\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN, Ireland and CHICAGO, Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that management will participate in the H.C. Wainwright BioConnect Conference\u00a0being held virtually from\u00a0January 11-14, 2021.\u00a0Corey Fishman, Chief Executive Officer, will provide a company overview and business update. The Company\u2019s presentation will be available on-demand through the H.C. Wainwright conference portal, beginning on\u00a0Monday, January 11th\u00a0at\u00a06:00 a.m. Eastern Time. The presentation may also be accessed by visiting the \u201cInvestors\u201d section of the Company\u2019s website under the \u201cEvents and Presentations\u201d tab at www.iterumtx.com. About Iterum Therapeutics plc &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-409960","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DUBLIN, Ireland and CHICAGO, Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that management will participate in the H.C. Wainwright BioConnect Conference\u00a0being held virtually from\u00a0January 11-14, 2021.\u00a0Corey Fishman, Chief Executive Officer, will provide a company overview and business update. The Company\u2019s presentation will be available on-demand through the H.C. Wainwright conference portal, beginning on\u00a0Monday, January 11th\u00a0at\u00a06:00 a.m. Eastern Time. The presentation may also be accessed by visiting the \u201cInvestors\u201d section of the Company\u2019s website under the \u201cEvents and Presentations\u201d tab at www.iterumtx.com. About Iterum Therapeutics plc &hellip; Continue reading &quot;Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-06T22:03:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTc3OCMzOTA3Nzk4IzIxMjA2NzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference\",\"datePublished\":\"2021-01-06T22:03:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\\\/\"},\"wordCount\":686,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTc3OCMzOTA3Nzk4IzIxMjA2NzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\\\/\",\"name\":\"Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTc3OCMzOTA3Nzk4IzIxMjA2NzM=\",\"datePublished\":\"2021-01-06T22:03:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTc3OCMzOTA3Nzk4IzIxMjA2NzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTc3OCMzOTA3Nzk4IzIxMjA2NzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference - Market Newsdesk","og_description":"DUBLIN, Ireland and CHICAGO, Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that management will participate in the H.C. Wainwright BioConnect Conference\u00a0being held virtually from\u00a0January 11-14, 2021.\u00a0Corey Fishman, Chief Executive Officer, will provide a company overview and business update. The Company\u2019s presentation will be available on-demand through the H.C. Wainwright conference portal, beginning on\u00a0Monday, January 11th\u00a0at\u00a06:00 a.m. Eastern Time. The presentation may also be accessed by visiting the \u201cInvestors\u201d section of the Company\u2019s website under the \u201cEvents and Presentations\u201d tab at www.iterumtx.com. About Iterum Therapeutics plc &hellip; Continue reading \"Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-06T22:03:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTc3OCMzOTA3Nzk4IzIxMjA2NzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference","datePublished":"2021-01-06T22:03:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/"},"wordCount":686,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTc3OCMzOTA3Nzk4IzIxMjA2NzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/","name":"Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTc3OCMzOTA3Nzk4IzIxMjA2NzM=","datePublished":"2021-01-06T22:03:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTc3OCMzOTA3Nzk4IzIxMjA2NzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTc3OCMzOTA3Nzk4IzIxMjA2NzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-participate-in-h-c-wainwright-bioconnect-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=409960"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409960\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=409960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=409960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=409960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}